FINWIRES · TerminalLIVE
FINWIRES

Tabcorp Likely Faces Remediation Costs from Austrac Probe, But Sell-Off Overdone, Jarden Says

作者

-- Tabcorp Holdings (ASX:TAH) likely faces remediation costs in a new regulatory enforcement investigation, and repeat offender status is also a risk, but neither of those factors justifies the magnitude of the sell-off in the company's stock, Jarden said in a Thursday note.

The Australian Transaction Reports and Analysis Center (AUSTRAC) is investigating the company's compliance with anti-money laundering and counter-terrorism financing obligations, citing concerns about its ability to identify and mitigate risks.

Jarden noted there is no certainty of a financial penalty as the regulator's disclosure stated that all outcomes are on the table, while previous cases show that a zero-penalty result is possible when the regulator is satisfied with cooperation.

AUSTRAC's previous gambling sector penalties have ranged from zero to AU$450 million, the equity research firm said, adding that it views top-line implications for Tabcorp as limited.

The company's shares fell sharply after the disclosure of the probe, and at those levels, "the stock appears to be factoring a cost impost well in excess of what the precedent set supports," Jarden said.

It maintained an overweight rating on Tabcorp with a target price of AU$1.05, saying it will revisit those assessments if Austrac files civil penalty proceedings or Tabcorp takes on provisions related to the case.

The company's shares fell 13% in recent Friday trade.

相關文章

Asia

阿波羅微系統公司斬獲價值5.1億印度盧比的訂單;股價上漲4%。

根據週五提交給印度證券交易所的文件顯示,國防製造商阿波羅微系統公司(Apollo Micro Systems,NSE:APOLLO,BOM:540879)已獲得總價值5.103億印度盧比的新訂單。 其中,來自印度國防部的訂單價值1.748億盧比,來自公共部門國防企業的合約價值9,530萬盧比,來自私營企業的訂單價值2.402億盧比。 該公司股價在最近的交易中上漲了近4%。

$BOM:540879$NSE:APOLLO
Asia

PKU HealthCare已獲準進行託法替尼檸檬酸鹽的市場推廣。

根據週五深圳證券交易所發布的公告顯示,北京康康醫療(SHE:000788)已獲得中國國家藥品監督管理局批准,上市銷售託法替尼檸檬酸鹽。 該藥物是一種強效的Janus激酶(JAK)抑制劑,主要用於治療慢性自體免疫疾病,包括僵直性脊椎炎、類風濕性關節炎和乾癬性關節炎。 受此消息提振,北京康康醫療股價在午後交易中上漲1%。

$SHE:000788
Asia

受關稅和成本壓力影響,豐田預計2027財年利潤將下降

豐田汽車(TYO:7203)週五在東京證券交易所提交的文件中預測,受中東局勢緊張導致原物料和能源成本上漲的影響,預計2027財年利潤將下降。 這家汽車製造商預計,截至2027年3月的財年,歸屬於股東的淨利潤將下降22%至3兆日圓,每股基本收益預計為251.25日圓。營收預計將小幅成長至51兆日圓。 截至2026年3月的財年,豐田公佈的歸屬於股東的淨利為3.848兆日圓,年減19%;營收成長5.5%至50.7兆日圓。每股盈餘從上年的359.56日圓降至295.25日圓。 該公司將年度股利從每股 90 日圓提高到 95 日圓,並預測 2027 財年將派息至每股 100 日圓。

$TYO:7203